Praesidia unequivocally believes in the power of collaboration. When the objective is to achieve the best possible solution, contributions from every available resource is the obvious way forward. We are already collaborating with several academic labs and research hospitals in the USA, Canada and India.

We remain continuously interested in new partnering opportunities with academic labs, biopharmaceutical companies and research hospitals from around the globe.

PIPELINE EXPANSION

Small molecule or biologics with proof-of-concept and pre-clinical data that can leverage our platform to increase specificity and/or reduce systemic toxicity.

PLATFORM APPLICATION

We are actively pursuing partnership with external labs and companies to value add to their pipeline by leveraging our Linker Technology to make the potential drug candidates more targeted and to reduce non-specific toxicity.

For example, a drug candidate with CNS application has great efficacy but has severe systemic toxicity. Our platform can potentially target this drug across the Blood Brain Barrier, without needing an antibody. Our Linker Enzyme Substrate System can also lessen the availability of the active drug in non-targeted organs, thereby reducing its toxic effects in those organs.

TO WORK TOGETHER, WRITE TO US